ImmunityBio and Iovance Stock Dynamics Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Should l Buy IBRX?
Source: stocktwits
- Stock Performance Comparison: IBRX's stock has fallen over 7% this week, dropping to $9 on Wednesday, while IOVA's stock has gained nearly 11%, reaching $4.26 on the same day, indicating differing market sentiments that could influence investor decisions.
- Sales Revenue Growth: ImmunityBio generated $113 million in revenue from Anktiva in 2025, up approximately 700% year-over-year, while Iovance reported about $87 million in Q4, exceeding estimates of $81.01 million, demonstrating strong market demand for both companies' therapies.
- Analyst Outlook Assessment: Analyst estimates from Koyfin suggest ImmunityBio has price targets ranging from $9 to $23, with an average target of $14.75 implying a 64% upside from current levels, while Iovance's targets range from $2 to $16, averaging $8.8, indicating a potential 107% upside, reflecting differing market expectations for both firms.
- Clinical Trial Progress: ImmunityBio's Quilt 2.005 trial shows that 85% of patients maintained a complete response at six months with Anktiva and BCG combination therapy, while Iovance's trial in new tumor types shows a 50% response rate, indicating positive advancements in expanding market potential for both companies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.000
Low
5.00
Averages
7.33
High
9.00
Current: 10.000
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Set to Announce Q4 Earnings with Mixed Estimates
- Earnings Announcement Date: ImmunityBio is set to release its Q4 earnings on March 3rd after market close, with market participants keenly awaiting its financial performance amid a competitive biopharmaceutical landscape.
- Earnings Expectations: The consensus EPS estimate stands at -$0.08, indicating ongoing challenges in profitability that could affect investor confidence in the stock.
- Revenue Projections: The consensus revenue estimate is $44.77 million, reflecting a substantial year-over-year growth of 521.8%, which highlights significant market demand but may raise concerns due to high base effects.
- Estimate Revision Trends: Over the past three months, there have been no upward revisions for EPS or revenue estimates, with one downward revision each, suggesting analysts' cautious outlook on the company's future performance, potentially impacting stock price movements.
See More
ImmunityBio and Iovance Stock Dynamics Analysis
- Stock Performance Comparison: IBRX's stock has fallen over 7% this week, dropping to $9 on Wednesday, while IOVA's stock has gained nearly 11%, reaching $4.26 on the same day, indicating differing market sentiments that could influence investor decisions.
- Sales Revenue Growth: ImmunityBio generated $113 million in revenue from Anktiva in 2025, up approximately 700% year-over-year, while Iovance reported about $87 million in Q4, exceeding estimates of $81.01 million, demonstrating strong market demand for both companies' therapies.
- Analyst Outlook Assessment: Analyst estimates from Koyfin suggest ImmunityBio has price targets ranging from $9 to $23, with an average target of $14.75 implying a 64% upside from current levels, while Iovance's targets range from $2 to $16, averaging $8.8, indicating a potential 107% upside, reflecting differing market expectations for both firms.
- Clinical Trial Progress: ImmunityBio's Quilt 2.005 trial shows that 85% of patients maintained a complete response at six months with Anktiva and BCG combination therapy, while Iovance's trial in new tumor types shows a 50% response rate, indicating positive advancements in expanding market potential for both companies.
See More
U.S. Markets Increased on Wednesday; Moderna Led the Gains
- U.S. Stock Market Performance: Stock indexes in the U.S. closed higher on Wednesday, indicating a positive market trend.
- Index Gains: The S&P 500 gained 1.29%, the Dow Jones increased by 0.78%, and the Nasdaq rose by 0.49%.
See More
ImmunityBio Prepares Anktiva Launch in Saudi Arabia Amid Tensions
- Significant Revenue Growth: ImmunityBio's ANKTIVA saw net revenues grow approximately 700% to $113 million in 2025, with projections indicating a further increase to $195 million in 2026, highlighting strong market demand and product potential.
- Launch Preparations in Saudi Arabia: Amid escalating geopolitical tensions in the Middle East, ImmunityBio is actively preparing for the launch of ANKTIVA in Saudi Arabia, planning to work closely with local authorities to manage imports, demonstrating the company's commitment to seizing market opportunities.
- Market Reaction: Despite Piper Sandler raising ImmunityBio's price target from $7 to $12 and maintaining an 'Overweight' rating, shares of IBRX fell 8% on Wednesday afternoon, reflecting investor concerns regarding the upcoming launch.
- User Sentiment Shift: On Stocktwits, retail sentiment around IBRX stock shifted from 'bullish' to 'neutral' over the past 24 hours, while message volume remained high, indicating a cautious outlook among investors regarding the company's future.
See More
S&P 500 Futures Hold Steady in Pre-Market Session; Moderna and SSR Mining Take the Lead
- Market Opening: U.S. stock markets are set to open in two hours.
- Moderna Inc. Performance: Moderna Inc. (MRNA) saw an 11.0% increase in pre-market trading.
- SSR Mining Inc. Performance: SSR Mining Inc. (SSRM) experienced a 9.2% rise in pre-market trading.
- Overall Market Sentiment: The pre-market gains indicate positive sentiment among investors for these companies.
See More
Wall Street Declines as Oil Prices Surge Amid Middle East Tensions
- Market Volatility: Wall Street closed lower on Tuesday, with the S&P 500 down 0.9% and the Nasdaq sliding 1%, reflecting investor concerns over potential disruptions to energy supplies amid escalating tensions in the Middle East.
- Surge in Oil Prices: Both Brent and WTI crude oil prices jumped over 4.5%, with Brent rising more than 12% over two sessions, indicating that geopolitical risks are driving significant volatility in global energy markets.
- Trump's Intervention: President Trump announced that the U.S. would provide insurance guarantees and potentially naval escorts for vessels transiting the Strait of Hormuz, aiming to ensure the continued flow of energy, highlighting the U.S.'s critical role in global energy security.
- Investor Sentiment Turns Bearish: Retail sentiment towards the SPDR S&P 500 ETF Trust and Invesco QQQ Trust shifted to 'bearish', reflecting market unease about future economic prospects, particularly in light of rising oil prices and instability in the Middle East.
See More
ImmunityBio Set to Announce Q4 Earnings with Mixed Estimates
- Earnings Announcement Date: ImmunityBio is set to release its Q4 earnings on March 3rd after market close, with market participants keenly awaiting its financial performance amid a competitive biopharmaceutical landscape.
- Earnings Expectations: The consensus EPS estimate stands at -$0.08, indicating ongoing challenges in profitability that could affect investor confidence in the stock.
- Revenue Projections: The consensus revenue estimate is $44.77 million, reflecting a substantial year-over-year growth of 521.8%, which highlights significant market demand but may raise concerns due to high base effects.
- Estimate Revision Trends: Over the past three months, there have been no upward revisions for EPS or revenue estimates, with one downward revision each, suggesting analysts' cautious outlook on the company's future performance, potentially impacting stock price movements.
See More
ImmunityBio and Iovance Stock Dynamics Analysis
- Stock Performance Comparison: IBRX's stock has fallen over 7% this week, dropping to $9 on Wednesday, while IOVA's stock has gained nearly 11%, reaching $4.26 on the same day, indicating differing market sentiments that could influence investor decisions.
- Sales Revenue Growth: ImmunityBio generated $113 million in revenue from Anktiva in 2025, up approximately 700% year-over-year, while Iovance reported about $87 million in Q4, exceeding estimates of $81.01 million, demonstrating strong market demand for both companies' therapies.
- Analyst Outlook Assessment: Analyst estimates from Koyfin suggest ImmunityBio has price targets ranging from $9 to $23, with an average target of $14.75 implying a 64% upside from current levels, while Iovance's targets range from $2 to $16, averaging $8.8, indicating a potential 107% upside, reflecting differing market expectations for both firms.
- Clinical Trial Progress: ImmunityBio's Quilt 2.005 trial shows that 85% of patients maintained a complete response at six months with Anktiva and BCG combination therapy, while Iovance's trial in new tumor types shows a 50% response rate, indicating positive advancements in expanding market potential for both companies.
See More
U.S. Markets Increased on Wednesday; Moderna Led the Gains
- U.S. Stock Market Performance: Stock indexes in the U.S. closed higher on Wednesday, indicating a positive market trend.
- Index Gains: The S&P 500 gained 1.29%, the Dow Jones increased by 0.78%, and the Nasdaq rose by 0.49%.
See More
ImmunityBio Prepares Anktiva Launch in Saudi Arabia Amid Tensions
- Significant Revenue Growth: ImmunityBio's ANKTIVA saw net revenues grow approximately 700% to $113 million in 2025, with projections indicating a further increase to $195 million in 2026, highlighting strong market demand and product potential.
- Launch Preparations in Saudi Arabia: Amid escalating geopolitical tensions in the Middle East, ImmunityBio is actively preparing for the launch of ANKTIVA in Saudi Arabia, planning to work closely with local authorities to manage imports, demonstrating the company's commitment to seizing market opportunities.
- Market Reaction: Despite Piper Sandler raising ImmunityBio's price target from $7 to $12 and maintaining an 'Overweight' rating, shares of IBRX fell 8% on Wednesday afternoon, reflecting investor concerns regarding the upcoming launch.
- User Sentiment Shift: On Stocktwits, retail sentiment around IBRX stock shifted from 'bullish' to 'neutral' over the past 24 hours, while message volume remained high, indicating a cautious outlook among investors regarding the company's future.
See More
S&P 500 Futures Hold Steady in Pre-Market Session; Moderna and SSR Mining Take the Lead
- Market Opening: U.S. stock markets are set to open in two hours.
- Moderna Inc. Performance: Moderna Inc. (MRNA) saw an 11.0% increase in pre-market trading.
- SSR Mining Inc. Performance: SSR Mining Inc. (SSRM) experienced a 9.2% rise in pre-market trading.
- Overall Market Sentiment: The pre-market gains indicate positive sentiment among investors for these companies.
See More
Wall Street Declines as Oil Prices Surge Amid Middle East Tensions
- Market Volatility: Wall Street closed lower on Tuesday, with the S&P 500 down 0.9% and the Nasdaq sliding 1%, reflecting investor concerns over potential disruptions to energy supplies amid escalating tensions in the Middle East.
- Surge in Oil Prices: Both Brent and WTI crude oil prices jumped over 4.5%, with Brent rising more than 12% over two sessions, indicating that geopolitical risks are driving significant volatility in global energy markets.
- Trump's Intervention: President Trump announced that the U.S. would provide insurance guarantees and potentially naval escorts for vessels transiting the Strait of Hormuz, aiming to ensure the continued flow of energy, highlighting the U.S.'s critical role in global energy security.
- Investor Sentiment Turns Bearish: Retail sentiment towards the SPDR S&P 500 ETF Trust and Invesco QQQ Trust shifted to 'bearish', reflecting market unease about future economic prospects, particularly in light of rising oil prices and instability in the Middle East.
See More
